{"nctId":"NCT00372060","briefTitle":"MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)","startDateStruct":{"date":"2006-08-21","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":134,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin phosphate","Drug: Comparator: pioglitazone"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: sitagliptin phosphate (MK0431)","Drug: Comparator: pioglitazone","Drug: Comparator: placebo (unspecified)"]}],"interventions":[{"name":"sitagliptin phosphate","otherNames":["MK0431"]},{"name":"Comparator: sitagliptin phosphate (MK0431)","otherNames":["MK0431"]},{"name":"Comparator: pioglitazone","otherNames":[]},{"name":"Comparator: placebo (unspecified)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients Have Type 2 Diabetes Mellitus\n* On Diet/Exercise Therapy And Pioglitazone As Monotherapy\n\nExclusion Criteria:\n\n* Patients Have Type 1 Diabetes Mellitus","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c ) at Week 12","description":"Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 12","description":"Change from baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.2","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in 2 Hour Postprandial Glucose at Week 12","description":"Change from baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.7","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Hemoglobin A1c (HbA1c ) at Week 52","description":"Change from the last value before receiving sitagliptin therapy: Week 0 for Sitagliptin/Sitagliptin group and Week 12 for the Placebo/Sitagliptin group.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":null},{"groupId":"OG001","value":"-0.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Blood creatine phosphokinase increased","Weight increased","Osteoarthritis"]}}}